Biotest AG: Biotest significantly increases sales and earnings target for 2007
Biotest AG / Half Year Results/Forecast
Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Dreieich, 19 July 2007. According to provisional figures, the Biotest Group
recorded sales totalling EUR 158.4 million in the first six months of 2007,
outperforming the previous year's figure (EUR 137.2 million) by 15.5%.
Earnings before interest and tax (EBIT) amounted to EUR 18.2 million, which
is 27.3% up on the comparative figure of EUR 14.3 million in 2006. The
Pharmaceutical segment achieved particularly dynamic growth, while
Diagnostic sales recorded a moderate rise, driven by strong business in
microbiology.
In the light of the positive results achieved in the first six months, the
Board of Management is now expecting sales growth of between 12% and 15%
for the 2007 as a whole (previous target range: 5% to 7%), with a similar
rise in EBIT.
Detailed figures outlining Biotest's business performance in the first six
months of 2007 will be published on 10 August 2007.
About Biotest
Biotest AG, Dreieich, Germany, is a company that researches and
manufactures pharmaceutical, biotherapeutic and diagnostic products and has
specialised in immunology and haematology. In its Pharmaceutical segment,
Biotest develops immunoglobulins, clotting factors and albumins based on
human blood plasma. These are used for diseases of the immune system or
haematopoietic system. In the Biotherapeutic segment, Biotest researches
into the clinical development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and blood cancer. The Diagnostic
segment spans reagents and serology and microbiology systems which are
used, for example, in blood transfusions. Biotest has around 1,200
employees worldwide and its shares are listed in the Frankfurt Stock
Exchange's Prime Standard.
Biotest AG:
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Marion Wendorff, Tel: +49 (0) 6103 801-520, e-mail:
marion_wendorff@biotest.de
Fax: +49 (0) 6103 801-7840
WKN, ISIN ordinary share: 522720, DE0005227201
WKN, ISIN preference share: 522723, DE0005227235
Listed: Prime Standard/official trading
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
DGAP 19.07.2007
----------------------------------------------------------------------
Language: English
Issuer: Biotest AG
Landsteinerstr. 5
63303 Dreieich Deutschland
Phone: +49 - 6103 / 801 - 0
Fax: +49 - 6103 / 801 - 150
E-mail: mail@biotest.de
Internet: www.biotest.de
ISIN: DE0005227201, DE0005227235
WKN: 522720, 522723
Indices:
Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in
Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
